SCTC21C

Biologic (subtype unspecified)

Phase 3underway

Evidence outlook · registrational

Multiple Myeloma: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2027-12.

Also in development:Systemic Lupus Erythematosus · Phase 1/2AL Amyloidosis · Phase 3IgA Nephropathy · Phase 1/2

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Phase 1/2 (2)
IgA Nephropathy
Systemic Lupus Erythematosus
Phase 1 (1)
Other / comorbidity
NCT06252298 · Sinocelltech Ltd.
2024-02-28 – 2027-02-28 · Relapsed or Refractory Hematologic Malignancies
What this study did

Competitive landscape

This mechanism is crowded: 13 other tracked programmes target it, 2 of them ahead of this one.

This drug's own stage for AL Amyloidosis: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
SCTC21C: this drugPhase 3Biologic (subtype unspecified)CD38not yet gradedNo reviewed efficacy summary in this indication
Anselamimab (Amlypave)Phase 3Monoclonal antibody—not yet gradedNo reviewed efficacy summary in this indication
DaratumumabPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
EtentamigPhase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
BirtamimabDiscontinuedMonoclonal antibodyMisfolded immunoglobulin light chain (AL amyloid)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow SCTC21C to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (4)
April 2027 (1)
Phase 1/2Systemic Lupus ErythematosusNot yet recruiting
Est. primary completion 2027-04 · NCT07538154 · CT.gov ↗
What to watch
September 2027 (1)
Phase 1/2IgA NephropathyNot yet recruiting
Est. primary completion 2027-09 · NCT06774664 · CT.gov ↗
What to watch
December 2027 (2)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-12 · NCT07297329 · CT.gov ↗
What to watch
Phase 3AL AmyloidosisRecruiting
Est. primary completion 2027-12 · NCT07388602 · CT.gov ↗
What to watch

See the full readout calendar ↗